Phase II Study of Irinotecan and Cisplatin as First-Line Chemotherapy in Advanced or Recurrent Cervical Cancer
| Autor: | Shinji Sato, Masanori Hatae, Fumitaka Saji, Kiichiro Noda, Yoshiteru Terashima, Ryouichi Kudoh, Toru Sugiyama, Michiaki Yakushiji, Yutaka Tomoda, Takeshi Takahashi, Shoshichi Takeuchi, Ikeda M, Naohiko Umesaki, Akira Yajima, Yasuo Ohashi, Masamichi Hiura |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty medicine.medical_treatment Uterine Cervical Neoplasms Neutropenia Irinotecan Gastroenterology Drug Administration Schedule Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Prospective Studies Radical surgery Aged Neoplasm Staging Cervical cancer Chemotherapy business.industry General Medicine Middle Aged medicine.disease Antineoplastic Agents Phytogenic Surgery Regimen Treatment Outcome Oncology Camptothecin Female Cisplatin Topoisomerase I Inhibitors business Progressive disease medicine.drug |
| Zdroj: | Oncology. 58:31-37 |
| ISSN: | 1423-0232 0030-2414 |
| DOI: | 10.1159/000012076 |
| Popis: | Irinotecan (CPT-11) and cisplatin are singly active against cervical cancer. We evaluated the efficacy and toxicity of CPT-11 plus cisplatin as first-line chemotherapy in patients with advanced or recurrent cervical cancer. Twenty-nine chemotherapy-naive patients with advanced or recurrent cervical cancer were treated with CPT-11 (60 mg/m2) on days 1, 8, and 15 by intravenous infusion over 90 min, followed by cisplatin (60 mg/m2 i.v.) on day 1 over 90 min. The patients’ median age was 57 years (range 35–75). Nineteen patients (66%) had advanced primary disease. Six patients with recurrent disease (21%) had been treated with prior radiotherapy. The remaining 4 patients (14%) had residual or recurrent disease after radical surgery. The histologic diagnoses were squamous cell carcinoma in 25 patients (87%), adenocarcinoma in 3, and adenosquamous cell carcinoma in 1. All eligible patients were included in the toxicity and response analysis based on the intent to treat. Two patients (7%) achieved a complete response and 15 (52%) a partial response (overall response rate: 59%, 95% confidence interval; 41–74%). Stable disease was recorded in 6 patients (21%) and progressive disease in 3 patients (10%). In 3 patients, image-guided evaluation of response was judged to be unfeasible at the time of independent extramural review (10%). The median time to response was 32 days (range 16–62 days). The median survival was 27.7+ months (range, 6.4–52.8+ months). Two dose-limiting side effects were observed: grade 3 (28%) or 4 (45%) neutropenia and grade 3 (7%) or 4 (7%) diarrhea. Other severe toxicities included anemia (45%), thrombocytopenia (3%), nausea/vomiting (31%), and alopecia (7%). The combination of CPT-11 with cisplatin is an active regimen for treatment of advanced or recurrent cervical cancer albeit with a significant degree of myelosuppression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|